Renal Denervation Devices Market Report 2026

Renal Denervation Devices Market Overview

• Renal Denervation Devices market size has reached to $0.74 billion in 2025 • Expected to grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 32.4% • Growth Driver: The Surge In Renal Denervation Devices Market Fueled By Escalating Hypertension Rates • Market Trend: Advancements in Ultrasound Renal Denervation Devices A New Era in Hypertension Treatment • Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Renal Denervation Devices Market?

Renal denervation devices are minimally invasive medical devices used to treat hypertension (high blood pressure) that have not improved with other treatments. A catheter is passed into the renal arteries that ablate sympathetic nerves in the vessel wall using radiofrequency energy to allow greater blood flow to the kidneys. The main products of the renal denervation devices are simplicity renal denervation system, EnligHTN, vessix renal denervation system, iberis renal sympathetic denervation system, paradise renal denervation system and others. The simplicity renal denervation system is a medical apparatus that employs a catheter and generator to administer radiofrequency energy to the renal nerves. The renal denervation devices use various technologies including radiofrequency ablation, ultrasound energy-based RDN, brachytherapy, chemical ablation and other technologies that are used by end-users such as hospitals, cardiovascular research centers and others.

What Is The Renal Denervation Devices Market Growth Forecast?

The renal denervation devices market size is expected to see exponential growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to increasing regulatory approvals for renal denervation devices, rising adoption in outpatient settings, growing demand for long-term hypertension management solutions, expansion of clinical evidence supporting efficacy, increasing investment in next-generation ablation systems. Major trends in the forecast period include increasing adoption of catheter-based hypertension therapies, growing use of radiofrequency and ultrasound ablation technologies, rising focus on minimally invasive cardiovascular interventions, expansion of image-guided renal denervation procedures, enhanced emphasis on procedure safety and precision.

Global Renal Denervation Devices Market Segmentation

1) By Product: Simplicity Renal Denervation System, EnligHTN, Vessix Renal Denervation System, Iberis Renal Sympathetic Denervation System, Paradise Renal Denervation System, Other Products 2) By Technology: Radio Frequency Ablation, Ultrasound Energy-Based RDN, Other Technologies 3) By End-Users: Hospitals, Cardiovascular research centre, Other End-Users Subsegments: 1) By Simplicity Renal Denervation System: Catheter System, Accessories 2) By EnligHTN: Catheter System, Generator, Accessories 3) By Vessix Renal Denervation System: Balloon Catheter, Generator, Accessories 4) By Iberis Renal Sympathetic Denervation System: Catheter System, Accessories 5) By Paradise Renal Denervation System: Catheter System, Accessories 6) By Other Products: Emerging Technologies, Alternative Devices

What Is The Driver Of The Renal Denervation Devices Market?

Increased prevalence of hypertension is expected to drive the growth of the renal denervation devices market in the future. Hypertension, also known as high blood pressure, is a condition in which the force of blood flowing through the blood vessels is consistently too high. Renal denervation is a catheter-based procedure that has emerged as a potential therapeutic option for patients with resistant hypertension. Renal denervation is a minimally invasive, investigational procedure to treat hypertension that hasn't responded to medication. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, high blood pressure contributed to or directly caused 664,470 deaths in the United States. Therefore, the increased prevalence of hypertension will promote the growth of the renal denervation devices industry.

Key Players In The Global Renal Denervation Devices Market

Major companies operating in the renal denervation devices market are Medtronic PLC, ReCor Medical Inc., Boston Scientific Corporation, Abbott Laboratories, Cordis Corporation, Terumo Corporation, Kona Medical Inc., St. Jude Medical LLC, Johnson & Johnson, Symple Surgical Inc., Cardiosonic Ltd., Mercator MedSystems Inc., Ablative Solutions Inc., Renal Dynamics Ltd., Vesalio LLC, Biotronik SE & Co. KG, Cook Medical LLC, Hansen Medical Inc., Merit Medical Systems Inc., AngioDynamics Inc., Covidien Ltd., Volcano Corporation

Global Renal Denervation Devices Market Trends and Insights

Major companies operating in the renal denervation devices market are focusing on developing ultrasound renal denervation (uRDN) to enhance treatment efficacy, reduce procedural complications, and provide a non-invasive alternative to traditional renal denervation techniques. Ultrasound renal denervation (uRDN) improves renal denervation devices by enabling precise, non-invasive energy delivery to renal nerves, effectively lowering blood pressure while protecting nearby tissues, and enhancing patient safety and comfort during the procedure. For instance, in November 2023, Recor Medical Inc., a US-based medical technology company, launched the Paradise uRDN system, an innovative ultrasound renal denervation device designed to treat hypertension in patients who haven't achieved blood pressure goals through standard lifestyle changes and medications. Featuring hydrocooling technology to protect the renal artery during treatment, this system represents a significant advancement in the renal denervation devices market by offering a new, nonpharmacologic approach to managing resistant hypertension and expanding treatment options for patients.

What Are Latest Mergers And Acquisitions In The Renal Denervation Devices Market?

In May 2025, Boston Scientific Corporation, a US-based biotechnology and biomedical engineering firm, acquired SoniVie Ltd. for $360 million. Through this acquisition, Boston Scientific plans to broaden its interventional cardiology offerings by incorporating SoniVie’s TIVUS intravascular ultrasound system, an investigational device developed for renal artery denervation (RDN) in the treatment of hypertension. SoniVie Ltd. is an Israel-based manufacturer of renal denervation devices.

Regional Outlook

Europe was the largest region in the renal denervation devices market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global renal denervation devices market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Renal Denervation Devices Market?

The renal denervation devices market consists of sales of products including a single electrode, multi-electrode, irrigated catheter, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.